logo
  

Biogen's Xirius Phase2/3 Study In XLRO Patients Fails To Meet Primary Endpoints

Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP.

The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints, such as a measure of visual acuity under low light conditions.

XLRP is a rare, inherited retinal disease that is associated with progressive vision loss. Cotoretigene toliparvovec or BIIB112 is an investigational AAV8 vector-based gene therapy administered by subretinal injection.

The company also announced a global collaboration and licensing agreement with ViGeneron GmbH to develop and commercialize gene therapy products based on adeno-associated virus vectors.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Airlines Group Inc. (AAL) said it flew 48 million passengers during the third-quarter, more than any other U.S. airline. Excluding special items, the company recorded its smallest loss since pandemic began. The company noted that its recovery took a pause in the third quarter due to the delta... San Jose, California -based Demaiz Inc., doing business as Mex-tamale Foods, is recalling around 20,759 pounds of pork and beef tamales citing misbranding and undeclared allergen, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The beef and pork tamale items produced between September 20 to October 14, 2021 contains sesame seeds, an allergen. McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022.
Follow RTT